Practice & clinical focus
Dr. M. trained in internal medicine at Columbia University Vagelos College of Physicians and Surgeons. Clinical focus is cardiometabolic disease, with particular interest in obesity pharmacotherapy, the regulatory landscape governing compounded medications, and the structural drivers of patient access to GLP-1 receptor agonists. Active board certification in internal medicine.
Role at WeighLossCompare
Dr. M. is the lead author of the audit’s published six-criterion methodology. In the inter-rater protocol, Dr. M. served as the first independent scorer across all fifteen audited sites, scoring blind to Dr. Thrush’s scores and to the final adjudicated outcomes. Dr. M. is responsible for editorial sign-off on the methodology paper and on all methodology-related corrections.
Areas of expertise
- Obesity pharmacotherapy — semaglutide, tirzepatide, liraglutide, and emerging dual and triple agonists
- Cardiovascular risk reduction in patients with obesity and type 2 diabetes
- 503A vs 503B compounding pharmacy regulation and FDA enforcement
- Editorial standards for medical comparison publications
- Methodology design for cross-site editorial audits
Conflicts of interest
Dr. M. has accepted no payment, equity, advertising, traffic, in-kind benefit, speaking honorarium, consulting fee, or commercial consideration from any GLP-1 telehealth provider, comparison site, or compounding pharmacy. Dr. M. does not consult for, advise, or hold financial interest in any entity audited in this publication. No industry-funded speaking engagements in the past five years.
If any of the above changes, the change will be disclosed on this page within seven days, logged in the public corrections log, and noted in any audit work product Dr. M. has authored or scored.
Contact
Editorial correspondence to Dr. M. should be directed to weighlosscompare@gmail.com with the subject line beginning “Attn: Dr. M.” All correspondence relating to the audit’s methodology or to specific scoring decisions is logged and may be cited in subsequent corrections or version updates.
Last reviewed: May 21, 2026. ← All editorial board members